TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14554068
Drug: Compoconnect (CC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compoconnect (CC) (Heraus Kulzer)
Study: 11574766
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with nitrosoureas
Study: 1448121
Drug: Trimethoprim-sulfamethoxazole (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (800 mg sulfamethoxazole and 160 mg trimethoprim once daily)
Study: 756475
Drug: Traditional denial-confrontation
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional denial-confrontation therapy emphasizing abstinence
Study: 28877822
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 μg/kg)
Study: 25723884
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus DEX (800 mg/m DEX 30 minutes before epirubicin administration)
Study: 25232512
Drug: RV capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: RV capsules (RV-CP)
Study: 20004330
Drug: Everolimus (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (2 mg/day)
Study: 20004330
Drug: Everolimus (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (4 mg/day)
Study: 20004330
Drug: Everolimus (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (3 ng/mL or less)
Study: 17225920
Drug: Citric acid
Normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citric acid addition (60 mg/portion) in product B
Study: 17225920
Drug: Phytase treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytase treatment in product C
Study: 17225920
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of citric acid addition, dephytinization, and iron supplementation
Study: 15455740
Drug: Topical subgingival
Normalized name: DOXYCYCLINE 10% SA SUBGINGIVAL SUSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical subgingival application of hyaluronic acid gel
Study: 16781604
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba (EGb 761) 240 mg per day
Study: 15046478
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of sustained release doxazosin for 7 days
Study: 15046478
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg of sustained release doxazosin after unsuccessful removal with 4 mg
Study: 3158277
Drug: Norfloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin (400 mg perorally, twice a day)
Study: 3158277
Drug: Trimethoprim‐sulfamethoxazole (160‐800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim‐sulfamethoxazole (160‐800 mg perorally, twice a day)
Study: 28459708
Drug: Pantoprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole (40 mg IV daily)
Study: 26107256
Drug: Ashtanga-based Yoga
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ashtanga-based Yoga Therapy (AYT) program for 8 weeks
Study: 18806616
Drug: Added treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Added treatment group (doxazosin 1‐4 mg and atenolol when needed)
Study: 8704192
Drug: G‐CSF 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF 300 microgram/d
Study: 1680414
Drug: Glycerol-containing peritoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerol-containing peritoneal dialysis fluid (G-PDF)
Study: 12641522
Drug: Standard 7-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 7-day therapy (rabeprazole 20 mg, clarithromycin 500 mg, and amoxicillin 1 g twice daily)
Study: 10708329
Drug: Verbal drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verbal drug cues
Study: 3028663
Drug: Alternating chemotherapy
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating chemotherapy with VP 16, ifosfamide, vindesine (VPIV), adriamycin, cisplatinum, vincristine (APO), and cyclophosphamide, methotrexate, CCNU (CMCC)
Study: 23849501
Drug: Rasagiline 1
Normalized name: rasagiline 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline 1 mg/day
Study: 22419863
Drug: GSK233705 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK233705 20 μg + salmeterol 50 μg twice-daily
Study: 22419863
Drug: GSK233705 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK233705 50 μg + salmeterol 50 μg twice-daily
Study: 21367594
Drug: Salmeterol 50
Normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 50 μg twice-daily
Study: 22419863
Drug: Tiotropium 18
Normalized name: TIOTROPIUM 18MCG CAP,INHL,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 μg once-daily
Study: 10617256
Drug: Calcitonin suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin suppositories (200 IU daily)
Study: 6690191
Drug: Ketanserin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (10 mg intravenous injection followed by 2 mg/h infusion)
Study: 22613690
Drug: Enhanced early
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced early communication therapy by speech and language therapists (SL therapy), up to three contacts per week for up to 16 weeks
Study: 20154405
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch (NG)
Study: 30635072
Drug: Telephone assistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone assistance to quit smoking (including psychological and psychoeducational support, and pharmacological treatment advice if required) for 12 months
Study: 19159075
Drug: Saline (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (control group, 10 ml)
Study: 7541358
Drug: Chlormadinone acetate
Normalized name: Chlormadinone acetate
DrugBank: Chlormadinone acetate (DB15903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlormadinone acetate (CMA) 100 mg/day for 2 weeks
Study: 21712623
Drug: APF gel
Normalized name: APF Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: APF gel application
Study: 15115681
Drug: control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: control group (spa therapy alone)
Study: 15121558
Drug: Rectal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal misoprostol (400 microg)
Study: 11641670
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin (20 units)
Study: 9853762
Drug: Triptorelin depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin depot treatment for 12 weeks before hysterectomy
Study: 8003098
Drug: Sitostanol esters
Normalized name: disodium ascorbyl sitostanol phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitostanol esters (< 1 g/day of free sterols) dissolved in rapeseed oil (RSO)
Study: 31825926
Drug: Li‐ESWT treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Li‐ESWT treatment (4 sessions on the PiezoWave2 unit)
Study: 30252774
Drug: HIGH (1.83
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIGH (1.83 g protein·kg·d)
Study: 30252774
Drug: MOD (1.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOD (1.20 g protein·kg·d)
Study: 30252774
Drug: LOW (0.94
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOW (0.94 g protein·kg·d)
Study: 25630442
Drug: Positive interaction
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive interaction between Agents A and B
Study: 25630442
Drug: B hitting
Approvals — FDA: no, EMA: no, PMDA: no
Description: B hitting Agent C while A was absent
Study: 22168590
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (hemoglobin threshold of 10 g/dL)
Study: 22168590
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (hemoglobin level <8 g/dL or symptoms of anemia at physician discretion)
Study: 16825703
Drug: Concentrated red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrated red grape juice (RGJ) 100 mL/d for 14 days
Study: 8351678
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release tablets (3 x 1 mg) (Treatment A)
Study: 14513919
Drug: Paroxetine coadministered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine coadministered with clonazepam followed by a tapered benzodiazepine discontinuation phase (PC-D)
Study: 11069324
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy of TDB 240 mg b.d., furazolidone 100 mg b.d., josamycin 1000 mg b.d. and famotidine 20 mg b.d. (BFJF group)
Study: 11069324
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy of TDB 240 mg b.d., furazolidone 100 mg b.d. and clarithromycin 250 mg b.d. (BFC group)
Study: 11069324
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy (BFJF group)
Study: 11069324
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (BFC group)
Study: 9081105
Drug: Heparin-coated cardiopulmonary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated cardiopulmonary bypass circuits (Duraflo II, n = 13)
Study: 8228636
Drug: Sitostanol esters
Normalized name: disodium ascorbyl sitostanol phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitostanol esters (3.4 g/day)
Study: 3511706
Drug: Phenobarbital (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital (500 mg intravenously)
Study: 22730101
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (ZOL) administered intravenously every 3-4 weeks
Study: 17013897
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (including 70 radical prostatectomy, 24 radiation, 10 endocrine treatment)
Study: 17013897
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (specifically radical prostatectomy)
Study: 12428233
Drug: DHEA (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (200 mg/day)
Study: 8138522
Drug: Imipramine (IMI)
DrugBank: Imipramine (DB00458)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imipramine (IMI) 2.5 mg/kg
Study: 19890181
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for symptomatic lumbar disc herniation
Study: 15199076
Drug: Daptomycin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daptomycin (6 mg/kg total body weight, administered intravenously over 30 minutes)
Study: 9393379
Drug: Immediate zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate zidovudine therapy
Study: 9393379
Drug: Deferred zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deferred zidovudine therapy
Study: 8260299
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (including diazepam, morphine, and no premedication)
Study: 30741725
Drug: Cognitive rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive rehabilitation intervention in addition to a routine therapy program
Study: 30741725
Drug: Routine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine therapy program
Study: 25768238
Drug: Intraperitoneal normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal normal saline (30 mL/kg)
Study: 25768238
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral acetazolamide (5 mg/kg)
Study: 22918839
Drug: Larger size
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larger size of drug network
Study: 21459216
Drug: High-dose fluocinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose fluocinolone acetonide insert (0.5 μg/day)
Study: 21459216
Drug: Low-dose fluocinolone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fluocinolone acetonide insert (0.2 μg/day)
Study: 21459216
Drug: Both low-
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both low- and high-dose inserts
Study: 19491822
Drug: Ketotifen 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen 4 mg
Study: 19491822
Drug: Ketotifen 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen 12 mg
Study: 9355816
Drug: Individual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual treatment plus family treatment (education and training in communication and problem-solving skills)
Study: 7681050
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose rate brachytherapy (1000 cGy at 10 mm depth for three fractions)
Study: 8454476
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose rate brachytherapy (750 cGy at 10 mm depth for three fractions)
Study: 30530580
Drug: Group-based chronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based chronic pain self-management course (2.5-hour weekly sessions for 6 weeks)
Study: 30530580
Drug: Low-impact outdoor
Normalized name: Cleartime Indoor & Outdoor Allergies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-impact outdoor group physical activity (1-hour weekly sessions for 6 weeks)
Study: 28317415
Drug: Dabigatran and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran and Warfarin
Study: 25985046
Drug: Continuation-phase cognitive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation-phase cognitive therapy (CT) for 8 months
Study: 12180580
Drug: remifentanil 1
Normalized name: remifentanil 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: remifentanil 1 microg/kg with propofol 0.5 mg/kg
Study: 12180580
Drug: saline 0.1
Normalized name: Simply Saline 0.154 MEQ/ML Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline 0.1 ml/kg
Study: 7864722
Drug: Lisinopril 2.5
Normalized name: lisinopril 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 2.5 to 5 mg/day
Study: 7864722
Drug: Lisinopril 32.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 32.5 to 35 mg/day
Study: 2532463
Drug: Cilazapril 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 5.0 mg orally
Study: 26165398
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg daily, increasing to a maximum of 2500 mg)
Study: 16874171
Drug: MenC‐TT vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenC‐TT vaccine coadministered with DTaP‐HBV‐IPV/Hib
Study: 11110850
Drug: TOS (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOS (20 g/d)
Study: 11110850
Drug: Reference treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference treatment (sucrose)
Study: 9168767
Drug: Metronidazole, gentamicin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole, gentamicin, and ampicillin (triple-antibiotic group)
Study: 8467026
Drug: Intravenous anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anesthesia with propofol/alfentanil combined with nitrous oxide
Study: 27182031
Drug: IDeg fixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDeg fixed dosing (at the same time each day)
Study: 24154700
Drug: palonosetron 0.075
Normalized name: palonosetron 0.075 MG in 1.5 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: palonosetron 0.075 mg i.v.
Study: 22117892
Drug: Functionally orientated
Normalized name: Papaver orientale seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functionally orientated treatment based on the shortened dental arch
Study: 20179007
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) - loading dose of 140 mg/kg IV over 1 hour followed by 70 mg/kg IV every 4 hours for a total of 12 doses.
Study: 18568325
Drug: Volatile oil
Normalized name: Volatile oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volatile oil of amomum (VOA) 0.5 mL, thrice per day
Study: 18568325
Drug: Western tertiary
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western tertiary medicinal treatment
Study: 15765452
Drug: Continuous subacromial
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subacromial infusion
Study: 12466507
Drug: Rhythm-control group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhythm-control group (serial cardioversions, antiarrhythmic drugs, oral anticoagulants)
Study: 12466507
Drug: Rate-control group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rate-control group (oral anticoagulants, rate-slowing medication)
Study: 16911813
Drug: Micronized fenofibrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized fenofibrate 200 mg/day
Study: 26940556
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg/day
Study: 1936479
Drug: Diet-Metformin combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet-Metformin combination
Study: 6179052
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg sulfinpyrazone
Study: 30120131
Drug: DAPP+ (dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPP+ (dual antiplatelet therapy pretreatment)
Study: 30120131
Drug: DAPP- (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPP- (no dual antiplatelet therapy pretreatment)
Study: 27377542
Drug: Testosterone (7·5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (7·5 g of 1% testosterone gel daily for 3 years)
Study: 25127170
Drug: Snack bars
Normalized name: Glucerna Snack Bars Dark Chocolate Almond
Approvals — FDA: no, EMA: no, PMDA: no
Description: Snack bars with 3 g β‐glucan
Study: 25127170
Drug: Snack bars
Normalized name: Glucerna Snack Bars Dark Chocolate Almond
Approvals — FDA: no, EMA: no, PMDA: no
Description: Snack bars with 6 g β‐glucan
Study: 25127170
Drug: Control bars
Normalized name: Medicated Bar Soap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control bars (0 g β‐glucan)
Study: 22149921
Drug: Subtotal nodal
Normalized name: chlorpheniramine maleate / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Iodal HD]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subtotal nodal radiation therapy
Study: 19234817
Drug: Intrathecal magnesium
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal magnesium sulfate 50 mg (3 ml)
Study: 19234817
Drug: Preservative-free 0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative-free 0.9% NaCl (3 ml)
Study: 15111532
Drug: Caffeine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (250 mg twice daily for 2 weeks)
Study: 9647457
Drug: Epidural block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural block with a combination of 8 ml of 1% mepivacaine and 40 mg of methylprednisolone (Group 3)
Study: 8207740
Drug: cilazapril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilazapril (2.5 mg daily)
Study: 8207740
Drug: nifedipine retard
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nifedipine retard (20 mg twice daily)
Study: 29066147
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg of methylprednisolone intravenously after anesthesia induction (n = 15)
Study: 17127043
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (n-3 fatty acids 3.6 g/day)
Study: 472913
Drug: Oral PGE2
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral PGE2 (5 mg total dose)
Study: 472913
Drug: Intravaginal PGE2
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravaginal PGE2 (4-6 mg in gel form)
Study: 16461091
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg sildenafil 45 minutes before coitus for 2 months (Group 2)
Study: 6992382
Drug: dimetikon 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: dimetikon 0.2 g 4 times daily, 3 days before examination
Study: 24529619
Drug: Medication for
Normalized name: SALICYLIC ACID 10 mg in 1 mL TOPICAL LOTION [Serious Skincare Continuously Clear Acne Medication For Problematic skin Dry Lo Pro All- Over Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication for headache prophylaxis
Study: 22759328
Drug: 10-day concomitant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day concomitant therapy (rabeprazole 20 mg twice daily, amoxicillin 1 g twice daily, metronidazole 400 mg three times a day, clarithromycin MR 1 g once daily)
Study: 22759328
Drug: 5-day concomitant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day concomitant therapy (rabeprazole 20 mg twice daily, amoxicillin 1 g twice daily, metronidazole 400 mg three times a day, clarithromycin MR 1 g once daily)
Study: 7676685
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg acetylsalicylic acid (Thrombo-ASS 50 mg)
Study: 7676685
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg (marketed preparation)
Study: 2151741
Drug: Corticosteroids and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids and/or cytotoxic drugs
Study: 15545305
Drug: Citalopram (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (dosage not specified)
Study: 17534686
Drug: Bevacizumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (15 mg/kg intravenously every 2 weeks)
Study: 17534686
Drug: Bevacizumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (15 mg/kg intravenously every 2 weeks) plus low-dose interferon alfa-2b (1 MU/m2 subcutaneously daily)